Home › Companies › MESO
Mesoblast
Market cap $1.54B 129.7M shares (vendor count, Nov 18, 2026) × $11.91 close Nov 17, 2026 · share count from the market-data vendor, not the SEC cover page
Most recent annual filing: 2026-08-27
Q3Q4Q1 ’27Q2Q3Q4Q1 ’28Q2
- Revascor LVAD BLA filing2026Revascor LVAD BLA filing, 2026, notable
- Capricor deramiocel read-through PDUFA dateNov 22, 2026Capricor deramiocel read-through PDUFA date, Nov 22, 2026, material
- Ryoncil pediatric corporate updateJan 2027Ryoncil pediatric corporate update, Jan 2027, routine
- Mesoblast corporate updateFeb 2027Mesoblast corporate update, Feb 2027, routine
- MSB-DR004 Rexlemestrocel-L topline2H 2027MSB-DR004 Rexlemestrocel-L topline, 2H 2027, thesis-defining
- Lonza manufacturing suite updateJul 1, 2027Lonza manufacturing suite update, Jul 1, 2027, routine
- Mesoblast corporate updateAug 2027Mesoblast corporate update, Aug 2027, routine
- Ryoncil adult SR-aGvHD interim4Q 2027Ryoncil adult SR-aGvHD interim, 4Q 2027, material
- Ryoncil CMC commitments manufacturing updateDec 31, 2027Ryoncil CMC commitments manufacturing update, Dec 31, 2027, routine
- Ryoncil adult SR-aGvHD readout2028Ryoncil adult SR-aGvHD readout, 2028, notable
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a
six-month window. Deeper blue means more of the thesis rides on the event; it is not a
view on the stock.
Pipeline (5 active programs)
Ryoncil
remestemcel-L-rknd · remestemcel-L - Acute Graft Versus Host Disease Approved Blood and Marrow Transplant Clinical Trials Network NCT02652130
Ryoncil
remestemcel-L
rexlemestrocel-L
REVASCOR
rexlemestrocel-L · MSB-DR003 · MSB-DR004
Ryoncil
remestemcel-L-rknd Technology platforms
Capital (as filed)
- Cash
- $130M cash and cash equivalents · Dec 31, 2025 (6-K)
- As stated in coverage
- $99.0M cash per the update of Nov 12, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (4)
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (4 calls)
Every verdict Biotech Distilled has published on Mesoblast, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-10-29 Watch Mesoblast Limited (MESO) - Scientific Deep Dive for Ryoncil, Rexlemestrocel-L and Pipeline Products At $13.39 the market prices roughly a 30% chance of a back-pain win, which looks about right but offers no margin of safety; revisit on DR004 data, Ryoncil recovery, LVAD BLA acceptance, or board independence confirmation.
- 2026-10-30 Watch UPDATE: Mesoblast (MESO) - The 4C Answers My Question, the Stock Doesn't Care None of the four upgrade triggers has fired; the receivable explanation for low cash burn didn't hold up, and at $15.67 the stock is above the probability-weighted fair-value range.
- 2026-11-03 Watch UPDATE: Mesoblast (MESO) - Two Chairs Empty, Eight Days Before the Vote Board independence cannot yet be judged until the 10 November AGM result is known; the PASS trigger has not yet fired despite two directors retiring with no named successors.
- 2026-11-13 Avoid UPDATE: Mesoblast (MESO) - The Lender Takes the Keys The board-independence trigger fired: the board no longer has an independent majority, and the largest holder and sole lender is now also running operations as interim COO, with the pay report taking a first strike.
- Avoid call · opened Nov 13, 2026 at $13.27 · -10.2% vs XBI -3.5% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Filings & releases (38)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first.
Releases captured from Oct 29, 2026;
filings from March 2026.
Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 17, 20266-KForeign issuer report · EX-99.1
- Nov 16, 20266-KForeign issuer report · EX-99.1
- Nov 15, 2026ReleaseMesoblast Showcased at ASX Premier Investor Day Eventvia aggregator
- Nov 12, 20266-KForeign issuer report · EX-99.1→ BD updateThe November 10 AGM handed George his board seat (Voigtman elected 81% FOR), retired Burns and Rose from the board, and installed George as Interim COO at $500K/year — making the largest shareholder simultaneously the company's lender, board member, and now chief operating officer.
- Nov 5, 2026ReleaseUse Of Ryoncil First Line After Steroids For Pediatric Acute Graft Versus Host Disease Highlighted In Key Opinion Leader Webinarvia aggregator
- Nov 3, 20266-KForeign issuer report · EX-99.1
- Nov 1, 2026ReleaseMesoblast Board Changesvia aggregator→ BD updateTwo directors retire ahead of Mesoblast's November 10 AGM — including Philip Krause, whose son's firm was hired to publish the LVAD BLA. The board changes partially address governance concerns I flagged, but the key question — whether George's nominee Voigtman still stands — remains unanswered.
- Oct 29, 2026ReleaseActivity Report for Quarter Ended September 30, 2026 (Appendix 4C)via aggregator→ BD updateSummary on the 6-K
- Oct 29, 20266-KForeign issuer report · EX-99.1→ BD updateMesoblast's Q1 FY2027 Appendix 4C arrived this morning with three simultaneous thesis-movers: the FDA greenlighted the LVAD BLA filing, the $57M receivable overhang was resolved in cash, and operating burn collapsed to $2.1M — all while the stock surged 17% pre-open.BD extracted 1 program update from this document → MESO pipeline
- Oct 16, 20266-KForeign issuer report · EX-99.1
- Oct 15, 20266-KForeign issuer report · EX-99.1
- Oct 13, 20266-KForeign issuer report · EX-99.1
- Sep 24, 20266-KForeign issuer report · EX-99.1
- Aug 27, 20266-KForeign issuer report · EX-99.1
- Aug 27, 202620-FAnnual report (foreign)
- Aug 25, 20266-KForeign issuer report · EX-99.1
- Aug 24, 20266-KForeign issuer report · EX-99.1
- Aug 18, 20266-KForeign issuer report · EX-99.1
- Jul 30, 20266-KForeign issuer report · EX-99.1
- Jul 21, 20266-KForeign issuer report · EX-99.1
- Jul 15, 20266-KForeign issuer report · EX-99.1
- Jul 14, 20266-KForeign issuer report · EX-99.1
- Jul 10, 20266-KForeign issuer report · EX-99.1
- Jul 1, 20266-KForeign issuer report · EX-99.1
- Jun 25, 20266-KForeign issuer report · EX-99.1
- Jun 10, 20266-KForeign issuer report · EX-99.1
- Apr 30, 20266-KForeign issuer report · EX-99.1
- Apr 29, 20266-KForeign issuer report · EX-99.1
- Apr 17, 20266-KForeign issuer report · EX-99.1
- Apr 15, 20266-KForeign issuer report · EX-99.1
- Apr 8, 20266-KForeign issuer report · EX-99.1
- Apr 8, 20266-KForeign issuer report · EX-99.1
- Apr 8, 20266-KForeign issuer report · EX-99.1
- Apr 8, 20266-KForeign issuer report · EX-99.1
- Mar 23, 20266-KForeign issuer report · EX-99.1
- Mar 18, 20266-KForeign issuer report · EX-99.1
- Mar 13, 20266-KForeign issuer report · EX-99.1
- Mar 12, 20266-KForeign issuer report · EX-99.1
1 more filing (13G holder notices, S-8, proxy material, SEC correspondence …)